Phase II study of afatinib for non-small cell lung cancer acquired resistance to osimertinib (North Japan Lung Cancer Study Group 1801)
Latest Information Update: 19 Jun 2019
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Dec 2018 Status changed from not yet recruiting to recruiting.
- 26 Dec 2017 New trial record